Prof. Dr. Juei-Tang Cheng

Institute of Medical Research, Chang Jung Christian University, Tainan, Taiwan

Dr. Cheng is a chair-professor at the Chang Jung Christian University and he also serves as a Senior Investigator in Chi-Mei Medical Center. During his PhD thesis research in pharmacology at Shizuoka Pharmaceutical College in Japan, he demonstrated that calcium-induced calcium release in smooth muscle. Then, he was invited as an associate professor at Tajen Pharmaceutical College in Taiwan. He found a nature fruit Guava in the alleviation of diabetic disorders. In 1986, he moved to the National Cheng Kung University to serve as an associate professor in pharmacology. He continued his favorite target, effects of natural products on diabetic complications. Depending on several findings, he promoted to the professor in the same university. Therefore, Dr. Cheng directed graduate students to investigate the pathophysiology of diabetes and the role of peptides in neuroendocrinology. He characterized the mediation neuropeptide Y in diabetic disorders and established the major role of beta-endorphin in metabolic regulation. In 1996, Dr. Cheng became the chairman of the Research Center for Traditional Chinese Medicine in his university. He used herbal products to demonstrate several findings in the alleviation of diabetic disorders. Therefore, Dr. Cheng got the Fellowship (FCP) from the American College of Clinical Pharmacology. He developed the role of opioid mu-receptors in the metabolic regulation and suggested endogenous receptors are helpful in the regulation of metabolism. Additionally, mediation of endogenous imidazoline receptors in diabetes has also been demonstrated in several publications. Since 2009, Dr. Cheng was retired and moved to the present university. His current research includes a systems biology approach to study the processes of metabolic disorders in efforts to identify new targets for the handling of diabetes and/or metabolic syndrome.

Dr. Cheng has been an active member of the American Diabetes Association (ADA) and New York Academy of Sciences, where he has been involved in the development of basic research to assist handling of metabolic disorders.  At national and international levels, he has served as a member of grant review panels and on the editorial advisory boards of multiple journals.

 

Updated 28 November 2023